inc buy pt impress result guidanc initi observ new ceo
hint much larger address market rais pt analyst nehal chokshi full summari
inc buy pt meet manag highlight new win higher valu busi rais
estim pt analyst allen klee cfa full summari
nation beverag corp sell pt result rel in-line deceler lacroix growth
data readout novemb analyst carolin palomequ full summari
beigen ltd bgne buy pt raf inhibitor collabor springwork analyst jason mccarthi ph
beyondspr inc buy pt differenti neulasta plinabulin demonstr anti-
 buy pt move closer tripl analyst jason
corpor event call maxim salesperson inform
beigen ltd bgne cover mccarthi institut group dinner nyc cfo howard liang tue oct
futur fit nutrit confer host vendetti nyc thur
domino pizza inc cover hq meet ann arbor ceo ritch allison cfo jeff
agilysi inc cover klee ndr nyc ceo ramesh srinivasan cfo toni pritchett thur sept
agilysi inc cover klee ndr boston ceo ramesh srinivasan cfo toni pritchett fri sept
net uep technolog inc uep cover klee ndr nyc cfo smith head india investor
net uep technolog inc uep cover klee ndr boston cfo smith head india
profir energi inc pfie cover jang ndr toronto ceo brenton hatch cfo ryan oviatt tue sept
result rel in-line deceler lacroix
today market hour report rel in-line juli
believ deceler lacroix sale growth led lower overal revenu
growth expect trend continu
gross margin lower expect believ primarili due higher
aluminum cost sg expens also grew slightli faster net sale
lead lower oper margin
april board discuss expedit incent compens
plan corpor manag advisor entiti own ceo
nick caporella although plan adopt view
possibl potenti harm minor sharehold would allow
inequit distribut cash ceo
bottom line would continu seller report in-line
result overal y/i revenu growth deceler third consecut quarter in-line
expect believ due slow growth lacroix coupl
continu stagnat compani brand aggreg expect
trend continu throughout rest april go-forward
revenu estim consensu moreov gross margin slightli lower
expect due higher aluminum cost headwind could continu
impact perform come quarter result factor well
on-going concern compani corpor govern disclosur practic
reiter sell rate
juli result summari today market hour report
revenu y/i rel in-line estim
consensu gross margin y/i
estim consensu ebitda y/i
slightli estim consensu ep
y/i slightli estim in-line consensu
lacroix deceler continu accord iri lacroix retail sale
multi-outlet end bevnet repres
y/i growth significantli lower peak growth level y/i
end evid overal revenu growth trend
deceler last three quarter project slower growth
lacroix coupl declin sale rest beverag portfolio
lead revenu deceler overal
oper margin compress second consecut quarter
oper margin experienc y/i declin believ primarili due higher
aluminum freight cost moreov ramp market effort
believ increment expenditur also neg impact
oper incom lacroix overal compani sale growth deceler
stock overvalu trade ev/ebitda estim compar
peer averag moreov trade price-to-earnings compar
peer averag price target impli trade
price-to-earnings signific discount peer due rel stagnant brand
exclud lacroix poor corpor govern lack transpar price
target support dcf use discount rate termin growth
click full note
move closer tripl
vertex announc two phase trial evalu tripl combin
tez/iva complet enrol homozyg
heterozygot data expect late second tripl
combo tez-iva phase trial complet enrol
report data
win see vertex evalu tripl
combin best regimen move forward potenti regulatori
approv studi demonstr signific
improv
conclus kalydeko orkambi symdeko continu grow
global tripl combin come closer view success
vertex cystic fibrosi cf franchis could potenti treat
cf popul expect symdeko launch continu
gain traction kalydeco continu layer addit elig patient
combin tripl combin data later year share
posit continu rise valu
tripl combo move closer data trial also get
shorter faster clinic trial get smaller shorter vertex
continu develop next-gen cf regimen tripl combin back
approv medicin particularli symdeko recal orkambi studi enrol
patient symdeko studi enrol patient drug
demonstr signific improv lung function week
symdeko backbon studi het/min patient
enrol patient four-week efficaci safeti data
safeti data collect requir regulatori submiss support
nda homozygot studi tripl
enrol patient four-week efficaci follow four-week run-in period tez/
iva safeti data het/min studi support nda
studi complet enrol week efficaci data expect late
studi complet enrol report week data
efficaci data two tripl regimen evalu determin
best move forward potenti nda file beyond week data point
potenti file vertex plan report addit longer term efficaci safeti
data
vertex remain leader cf galapago glgp nr report top-lin result
pelican trial evalu corrector orkambi
combin treatment reach primari endpoint result demonstr inferior
lung function result adjust benefit treatment vs placebo
vs intern goal critic partner nr decid
proceed second plan triplet combin studi review
partnership contrast tripl combin symdeko
backbon vertex continu move closer data late
potenti approv thu given lacklust data come glgp
advanc cf franchis vertex competitor vertex remain well-posit
continu domin cf space
click full note
impress result guidanc initi observ
new ceo hint much larger address market
strong result subscript q/q growth continu outpac
guidanc healthili consensusin earli inning impact
uniqu panw applic framework view
rais price target beat rais notabl
new ceo nikesh arora impli address larger
previous consid
strong result subscript q/q growth continu outpac
near-term expect highlight investor day review
deliv signific upsid surpris guidanc rais quarter
row note report result pre-asc adopt basi also
provid guidanc adopt re-stat base
re-stat de minimu impact revenu
bill provid analysi juli quarter result adopt
basi consist discuss around guidanc juli quarter
revenu y/i midpoint guidanc
beat eman product revenu midpoint guidanc
last three quarter product revenu beat day sale
outstand dso day use end ar/bil day y/i
indic quarter back-end load year-ago period
also note subscript revenu q/q outpac q/q mainten
revenu growth suggest increas effect attach rate instal base
mainten q/q revenu growth scale instal base believ
data point combin investor day data show gener
higher revenu per custom see figur page investor day note continu
indic current best-in-class cybersecur platform go well beyond
firewal product compani sale product metric expens
year ago divid bill current period improv y/i
materi better averag y/i deterior past four quarter
also report ebit y/i includ increment
opex invest associ compani acquisit secdo evid io
ep y/i well ahead midpoint guidanc
re-stat benefit ep
guidanc healthili consensusin earli
impact
uniqu panw applic framework view manag provid
oct midpoint revenu guidanc y/i
ahead consensu ep y/i includ
invest relat recent close secdo evid io acquisit
guidanc paramet impli bill increas y/i slight decel
jul y/i growth q/q compar year-ago season
declin q/q bill estim also impli sale product metric
improv impress y/i confid guidanc given
machin learn infus organically-develop sale tool give panw sale
team competit advantag take-away mid-term analyst day
manag content agre compani applic
framework enabl custom consum non-palo alto network secur softwar
without new hardwar applianc reson compani exist custom
drive expand well new custom add increasingli believ
impact panw applic framework prove sustain driver market
share gain given applic framework lack competit respons abil
drive upsel product revenu parti applic requir bandwidth
inning
run firewal attach subscript global protect wildfir url
filter threat prevent believ earli inning
impact panw applic framework drive increas wallet share
rais price target beat rais notabl
new ceo nikesh arora impli address total address
market larger previous consid given
out-performance guidanc estim dcf-base price target
increas termin period estim includ revenu
assum chang
defer revenu fcf/revenu ratio price target
also correspond multipl believ reason
given increas confid panw abil grow revenu excess
per year multipl year compar share current trade
long-term estim also assum product
ratio compar achiev
increasingli believ may track achiev target believ
current guidanc impli ratio y/i improv
like continu improv termin period revenu
estim compar opportun ceo nikesh arora cite one
five key observ compar manag
assert address introduct applic framework
increas assert increment gross cash ad
balanc sheet via convert debt rais quarter bring gross cash
signal new ceo nikesh arora look expand panw reach
address cyber-secur relat problem via acquisit perspect
would well-serv expand explicitli infrastructur autom
space-leverag nosql technolog compani alreadi network
secur product believ mani go-to-market synergi
infrastructur autom seamless network secur capabl
believ expans infrastructur autom may provid bridg
assess septemb analyst day new
ceo nikesh arora allud final note ceo nikesh arora interest
consolid rather integr consist success
strategi execut date show clear understand
sharehold accret acquisit requir realiz signific revenu synergi
click full note
differenti neulasta plinabulin
announc phase data demonstr prevent
patient receiv plinabulin poster titl
chemotherapy-induc neutropenia thrombocytopenia
nsclc
patient present intern associ
studi lung cancer iaslc
trial compar plinabulin vs neulasta patient receiv docetaxel
chemotherapi nsclc recommend dose
plinabulin data demonstr signific reduct incid
thrombocytopenia across four cycl studi effect
view expect demonstr neulasta arm studi
platelet count frequent side effect chemotherapi lead
bleed anemia requir platelet transfus neulasta
mitig effect data announc today add plinabulin
alreadi differenti profil includ anti-canc effect protect
neutrophil instead growth bone pain day administr
minut chemo vs plinabulin appear protect platelet
conclus much focu neutropenia space
neulasta biosimilar plinabulin continu demonstr differenti
profil improv safeti addit benefit
sever data point possibl regulatori file ahead
repres potenti inflect point stock
inflect point ahead phase studi phase portion initi data interim
data studi file approv china follow top-lin final
data studi nda file us lung cancer studi interim
plinabulin neutropenia space neulasta market potenti
first step life-cycl neulasta brand pegfilgrastim gener
annual target patient high risk chemotherapi induc neutropenia
cin occurr grade despit use pegfilgrastim still
though durat sever neutropenia reduc side effect includ
bone pain treatment must administ hospit day
chemo plinabulin administ time chemo patient go home
without bone pain could potenti allow expans moderate-
risk popul subject studi pegfilgrastim
recommend interestingli two drug complet differ may
addit one anoth like combin arm ad
on-going studi plinabulin given time chemo protect exist
neutrophil pegfilgrastim potenti lower dose given may
reduc cin dsn either drug alon view plinabulin also
demonstr reduct thrombocytopenia advers effect chemotherapi
prevent neulasta plinabulin may attract pegfilgrastim
produc aim take maintain signific share market also note
plinabulin demonstr anti-canc effect addit neutrophil protect
lung cancer studi studi lung cancer on-going
click full note
raf inhibitor collabor springwork
beigen announc compani enter global clinic
partnership springwork privat evalu raf dimer
inhibitor lifirafenib combin springwork mek inhibitor
patient solid tumor term agreement
parti share cost associ futur clinic studi
beigen expect initi studi evalu safeti
toler preliminari efficaci combin solid tumor
harbor ra raf mapk mutat
combin approach dysregul ras/raf/mek/erk
pathway common mani cancer resist ultim occur
target drug tumor find altern bypass pathway use
treatment target multipl effector pathway may effect
strategi overcom feedback loop use singl molecul
conclus present approv braf inhibitor market roch
rog nr zelboraf vemurafenib novarti nv nr tafinlar
dabrafenib proven effect raf dimer
lifirafenib may potenti address lifrafenib inhibit monom
dimer form braf view demonstr depth
beigen oncolog pipelin
target ras/raf/mek/erk pathway ra protein act upstream ras/
raf/mek/erk signal pathway raf mek downstream compon
integr upstream signal ra protein serv master regul number
signal cascad respons growth migrat surviv differenti
activ respons variou extern stimuli mutat ra present
human tumor make pathway critic area develop new cancer
treatment despit decad research anti-ras-specif therapi
approv date given frequenc mani cancer mani continu tri includ
onconova ontx buy ra mimet trial present target
high risk myelodysplast syndrom md combin approach meki
rafi beigen springwork could potenti overcom feedback loop
appear imped therapeut develop ras-mut tumor
lifirafenib small molecul raf kinas dimer inhibitor
develop monotherapi combin therapi
treatment cancer aberr mitogen-activ protein kinas mapk
pathway includ braf gene mutat kras/nra gene mutat
first gener braf inhibitor effect mapk pathway chain
protein cell commun signal receptor surfac
cell dna nucleu cell pathway play essenti role
regul cell prolifer surviv beigen hope develop treat
endometri cancer ovarian cancer pancreat cancer papillari thyroid carcinoma
current approv first-gener braf inhibitor vemurafenib dabrafenib
activ braf monom inhibit monom
also dimer form braf may potenti first-in-
click full note
complet data readout novemb
quantum genom announc finish enrol phase new-
trial firibastat hypertens trial ahead schedul data
expect mid-novemb
recruit compani recruit hypertens subject
mmhg diastol blood pressur mmhg overweight obes mean
bodi mass index kg/m minor african-
american hispan recruit took month throughout us
view faster-than-anticip recruit underscor unmet
need hypertens may especi acut among high-risk patient
across ethnic group less respons current therapeut
conclus view studi earli enrol potenti
earlier-than-expect hypertens data readout posit
compani stock data posit would establish proof concept
poc firibastat hypertens view would inform phase
design and/or posit program partnership
new-hop hypertens studi studi initi novemb
fulli enrol studi enrol overweight obes patient
hypertens resist current treatment patient receiv treatment
eight-week period initi dose daili may increas
daili primari endpoint trial chang blood pressur
baselin eight week treatment secondari endpoint includ chang
diastol blood pressur ambulatori blood pressur measur lab test
signific reduct blood pressur bp consid
prior studi four week treatment blood pressur
reduc patient higher baselin bp reduct
higher compani expect trial complet late addit
compani develop tablet singl daili dose vs twice day
arteri hypertens htn global major public health concern affect
one third world popul htn one lead risk factor coronari
heart diseas heart failur stroke renal insuffici complic htn
account million death world-wide year despit avail mani
antihypertens drug htn concomit risk factor still success
control hypertens patient popul african-
american aa htn occur earlier sever less control
higher morbid mortal us caucasian aa also less respons
monotherapi angiotensin convert enzym inhibitor ace-i angiotensin
receptor blocker obes higher salt-sensit low plasma renin activ
among possibl reason less robust blood pressur respons initi therapi
renin angiotensin system modul especi aa
click full note
meet manag highlight new win
higher valu busi rais estim pt
rais estim reflect rnet win mcdermott mdr nr fleet
contract lower-than-expect impact loss nr
remain posit compani gain market share improv
value-ad packag iot segment offer
new cfo ahlstrom bring strong background energi investor
think acquisit potenti expand scale rnet network
reach could add strateg valu abil cross-sel higher-end
reiter buy rate rais price target base
earn outlook improv meet rnet manag
increas confid compani growth strategi ceo steve picket
new cfo ahlstrom provid well-articul strategi expand market
serv add higher-valu offer compani announc win mcdermott
complet vessel fleet commun servic addit crew
valid compani strategi provid addit iot product
expect mcdermott contract larg off-set loss contract
addit remain posit compani cybersecur machin learn
segment new regul requir deliveri real-tim data on-shor facil
start april act catalyst cybersecur offer
help ensur secur uniqu encrypt methodolog also
posit compani plan develop stronger network gulf mexico
creat futur revenu stream final impress new cfo
ahlstrom strong background energi industri believ expertis
investor relat help articul growth stori
rais estim reflect new win less impact loss
contract base analysi believ mcdermott contract win
larg off-set loss contract addit research shown
market overst impact loss contract importantli given
differenti full solut offer compani gain market share result
rais estim factor net impact contract win also remain
posit compani system integr segment doubl backlog
end june august earn call new win busi
model signific oper leverag improv margin energi
market recov current margin around half
believ could upsid newli rais estim purchas
network provid captur synergi increas abil cross-sel
reiter buy rate rais price target
new price target base adjust ebitda estim
million previous valu stock base prior ebitda estim
million rais multipl reflect higher confid compani
earn outlook multipl reflect slight premium energi
servic compani trade factor newer busi area machin
learn cybersecur compar stock trade much higher multipl
also note compani similar busi model like tower stock also
trade significantli higher multipl addit encourag see kkr
compani largest sharehold buy share open market remain
posit industri fundament compani abil gener posit
downcycl oligopolist market structur high barrier entri
click full note
maxim analyst coverag univers
sector coverag
care well
industri infrastructur
receiv full disclosur compani maxim group coverag mention report pleas send
